The U.S. Food and Drug Administration (FDA) has approved Gammagard Liquid ERC (immune globulin infusion) for patients ages two years and older with primary immunodeficiencies.
Primary immunodeficiencies are a group of rare, genetic diseases affecting the immune system. There are over 200 different types of PIDs. Impaired immune system function causes patients to be at risk of developing chronic infections.
Gammagard liquid ERC is a ready-to-use immunoglobulin replacement therapy with an immunoglobulin A content of less than or equal to 2 µg/mL in a 10% solution. The therapy may be administered intravenously or subcutaneously. The treatment is expected to be available in 2026. Once available, the manufacturers (Takeda) plan to discontinue Gamagard S/D [immune globulin intravenous IgA less than 1 ug/ml in a 5% solution] and that transition should be complete by the end of 2027.
For more information, click here.
To learn more about primary immunodeficiency and other rare autoimmune conditions, visit https://checkrare.com/diseases/autoimmune-and-auto-inflammatory-disorders/
